Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK<sup>+</sup> NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigati...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2021-01-01
|
| Serija: | Pharmaceuticals |
| Teme: | |
| Online dostop: | https://www.mdpi.com/1424-8247/14/2/80 |
| Oznake: |
Brez oznak, prvi označite!
|